Evidence Brief: Mental Health Outcomes of Adults Hospitalized for COVID-19

Authors:
Stephanie Veazie, MPH
Brenda LaFavor, MD
Kathryn Vela, MLIS
Sarah Young, MPH
Nina A. Sayer, PhD
Kathleen Carlson, PhD
Maya O’Neil, PhD

WHAT’S NEW
Updated July 21, 2021
Search current as of March 2021

This update revises findings from our report published in March 2021. The review includes studies from an updated search and now focuses on the 17 studies (2 prospective cohort, 2 retrospective cohort, and 13 cross-sectional) that provide the best available evidence. We conclude that while many patients experience MH symptoms such as depression, anxiety, and insomnia during and in the 3 months following hospitalization for COVID-19, patients infrequently receive a new MH disorder diagnosis in the 6 months following hospitalization. However, some patients – such as women and those with more severe COVID-19 – may be at higher risk of poor MH outcomes.
PREFACE

The VA Evidence Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted healthcare topics of importance to clinicians, managers, and policymakers as they work to improve the health and healthcare of Veterans. These reports help:

- Develop clinical policies informed by evidence;
- Implement effective services to improve patient outcomes and to support VA clinical practice guidelines and performance measures; and
- Set the direction for future research to address gaps in clinical knowledge.

The program comprises three ESP Centers across the US and a Coordinating Center located in Portland, Oregon. Center Directors are VA clinicians and recognized leaders in the field of evidence synthesis with close ties to the AHRQ Evidence-based Practice Center Program and Cochrane Collaboration. The Coordinating Center was created to manage program operations, ensure methodological consistency and quality of products, and interface with stakeholders. To ensure responsiveness to the needs of decision-makers, the program is governed by a Steering Committee composed of health system leadership and researchers. The program solicits nominations for review topics several times a year via the program website.

Comments on this evidence report are welcome and can be sent to Nicole Floyd, Deputy Director, ESP Coordinating Center at Nicole.Floyd@va.gov.


This report is based on research conducted by the Evidence Synthesis Program (ESP) Coordinating Center located at the Portland VA Health Care System, Portland, OR, funded by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development. The findings and conclusions in this document are those of the author(s) who are responsible for its contents; the findings and conclusions do not necessarily represent the views of the Department of Veterans Affairs or the United States government. Therefore, no statement in this article should be construed as an official position of the Department of Veterans Affairs. No investigators have any affiliations or financial involvement (eg, employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties) that conflict with material presented in the report.
**TABLE OF CONTENTS**

Preface .............................................................................................................................................. i  
Executive Summary ........................................................................................................................ 1  
  Key Findings ........................................................................................................................... 1  
Evidence Brief ................................................................................................................................ 7  
Introduction ..................................................................................................................................... 7  
  Purpose ....................................................................................................................................... 7  
  Background .................................................................................................................................. 7  
  Scope ............................................................................................................................................ 8  
  Key Questions and Eligibility Criteria ......................................................................................... 8  
Methods ......................................................................................................................................... 11  
  Searches and Study Selection .................................................................................................... 11  
  Quality Assessment and Data Extraction .................................................................................... 11  
  Strength of Evidence Assessment ............................................................................................... 11  
  Synthesis of Data ........................................................................................................................ 11  
  Living Review ............................................................................................................................ 12  
Results ........................................................................................................................................... 13  
  Literature Flow ........................................................................................................................... 15  
  Key Question 1: Among adults who have been hospitalized for COVID-19, what is the prevalence of MH disorders during or after hospitalization? .................................................... 16  
  Key Question 2: How often do adults without preexisting MH conditions who have been hospitalized for COVID-19 develop new MH symptoms or a new MH diagnosis? ............... 17  
  Key Question 2A: How often do adults without preexisting MH conditions who have been hospitalized for COVID-19 develop new MH symptoms or a new MH diagnosis compared to those with outpatient COVID-19? ........................................................................ 18  
  Key Question 2B: How often do adults without preexisting MH conditions who have been hospitalized for COVID-19 develop new MH symptoms or a new MH diagnosis compared to adults hospitalized for other causes? ............................................................................. 19  
  Key Question 2C: Does the probability of developing new MH symptoms or diagnosis during or after hospitalization for COVID-19 vary by patient characteristics (eg, age, sex, race/ethnicity, comorbidities), COVID-19 disease severity, or level of care? .......... 19  
  Key Question 3: How often do adults with preexisting MH conditions who have been hospitalized for COVID-19 experience exacerbation of MH symptoms? ................................................ 22  
  Key Question 3A: How often do adults with preexisting MH conditions who have been hospitalized for COVID-19 experience exacerbation of MH symptoms compared to those with outpatient COVID-19? ..................................................................................... 22
Key Question 3B: How often do adults with preexisting MH conditions who have been hospitalized for COVID-19 experience exacerbation of MH symptoms compared to adults hospitalized for other causes? ........................................................................................................ 23

Key Question 3C: Does the probability of exacerbating MH symptoms during or after hospitalization for COVID-19 vary by patient characteristics (e.g., age, sex, race/ethnicity, comorbidities), COVID-19 disease severity, or level of care? ........................................................................................................ 23

Key Question 4: How often and what kinds of MH care do adults access during or after hospitalization for COVID-19? ........................................................................................................ 23

Key Question 4A: Does the type or extent of MH care used by adults during or after COVID-19 hospitalization differ compared to before hospitalization? ........................................................................................................ 23

Key Question 4B: Does the type or extent of MH care utilization differ for adults hospitalized for COVID-19 compared to adults receiving outpatient treatment for COVID-19? ........................................................................................................ 23

Key Question 4C: Does the type or extent of MH care utilization differ for adults hospitalized for COVID-19 compared to adults hospitalized for other causes? ........................................................................................................ 24

Key Question 4D: Does the type or extent of MH care utilization during or after hospitalization for COVID-19 vary by patient characteristics (e.g., age, sex, race/ethnicity, comorbidities), COVID-19 disease severity, or level of care? ........................................................................................................ 24

Key Question 5: What are the MH care resource needs among adults who have been hospitalized for COVID-19? ........................................................................................................ 24

Summary and Discussion ........................................................................................................ 25

Limitations ................................................................................................................................. 26

Gaps and Future Research ......................................................................................................... 26

Evolving Nature of COVID-19 and Mental Health .................................................................... 28

Conclusions ................................................................................................................................. 29

Acknowledgments ......................................................................................................................... 30

References ..................................................................................................................................... 31

TABLES AND FIGURES

Table 1. Overview of the Best Available Evidence Addressing Each Key Question .............. 3
Table 2. Key Questions and Eligibility Criteria ........................................................................ 9
Figure 1: Literature Flowchart ................................................................................................... 15
Table 3. Prevalence of MH Disorders in Patients Hospitalized for COVID-19 ..................... 17
Table 4. Prevalence of MH Disorders Among Patients Hospitalized for COVID-19 by Patient Characteristics, COVID-19 Disease Severity, and Level of Care .......................... 21
EXECUTIVE SUMMARY

Key Findings

- Seventeen studies (2 prospective cohort, 2 retrospective cohort, and 13 cross-sectional) that enrolled ≥ 200 participants provide the best available evidence on mental health (MH) outcomes among patients who have been hospitalized for COVID-19.

- Many patients may experience MH symptoms during and in the 3 months following hospitalization for COVID-19. Specifically, 30-39% of patients may experience anxiety symptoms, 24-40% insomnia symptoms, 20-26% obsessive-compulsive symptoms, and 10-15% PTSD symptoms. Estimates of depression symptom prevalence are more variable across studies (9-66%) due to differences in how symptoms were measured and reported (5 fair-quality cross-sectional studies, and 1 fair-quality prospective cohort study).

- The incidence of receiving a new MH disorder diagnosis in the 6 months after hospitalization for COVID-19 is probably low. Five percent of patients are likely to be diagnosed with a new mood disorder, 7% anxiety disorder, 3% insomnia, and 2% substance use disorder that was not diagnosed before the COVID-19 hospitalization (1 good-quality retrospective cohort study).

- Hospitalized COVID-19 patients are likely to have an elevated risk of receiving a new MH disorder diagnosis 6 months after COVID-19 diagnosis compared to outpatients with COVID-19 (1 good-quality retrospective cohort study). It is unknown whether the observed increased risk is due to hospitalization for COVID-19 specifically or hospitalization generally.

- The incidence of receiving a new psychotic disorder diagnosis in the 6 months following hospitalization for COVID-19 is probably very low (around 1%) (1 good-quality retrospective cohort study).

Background

The ESP Coordinating Center (ESP CC) is responding to a request from VA Central Office for an evidence brief on mental health (MH) outcomes of adults who have been hospitalized for COVID-19. Findings from this evidence brief will be used to inform national VA planning efforts to support Veterans who have been hospitalized for COVID-19 after they have been discharged from the hospital.

Methods

To identify studies, we searched MEDLINE, the WHO COVID-19 database, PsycINFO, and CINAHL from Dec 2019 to March 2021. We used prespecified criteria for study selection, data abstraction, and rating internal validity and strength of the evidence. See our PROSPERO protocol for our full methods (Registration # CRD42020199557).

In March 2020, the World Health Organization (WHO) declared the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), a pandemic. Although most people with COVID-19 experience no symptoms or mild fever, cough, shortness of breath, or fatigue, approximately 1 in 7 experience severe symptoms requiring hospitalization. In-hospital mortality for patients with COVID-19 is around 17%. Many hospitalized patients experience life-threatening complications such as bacterial pneumonia, sepsis, acute respiratory distress syndrome, and multi-organ failure. As a result of the stress of being hospitalized for a serious, highly transmissible illness during a pandemic,
experts warn that patients hospitalized with COVID-19 are at high risk of developing mental health symptoms and psychiatric disorders such as major depression, panic or other anxiety disorders, or post-traumatic stress disorder (PTSD), or of experiencing exacerbations of existing disorders. Veterans who receive care at the VA have high rates of comorbid medical disorders (16% report having 5 or more medical conditions) and high rates of preexisting mental health diagnoses (including depression [13.5%), PTSD [9.3%), substance use disorders [8.3%), anxiety disorders [4.8%], and serious mental illness [3.7%]) and may be at particularly high risk of developing new mental health symptoms or disorders, or of experiencing exacerbations of existing mental health symptoms or disorders.

In June 2020, the Department of Veterans Affairs (VA) Central Office requested that the VA Evidence Synthesis Program (ESP) produce 3 rapid evidence reviews on post-acute care needs for adults who have had COVID-19. The first 2 reviews focused on major organ damage and rehabilitation needs, respectively. This is the third review in the series and focuses on the mental health needs of adults who have been hospitalized with COVID-19. The purpose of this review is to compare the prevalence of mental health disorders among adults who have been hospitalized for COVID-19 to relevant comparison groups, assess whether mental health disorder prevalence varies by patient and disease characteristics, and ascertain patients’ mental health care utilization and resource needs. Findings from this evidence brief will be used to inform national VA planning efforts to support Veterans after hospital discharge for COVID-19.

We included cross-sectional and cohort studies that examined the prevalence of mental health disorders and clinical features, such as insomnia, among adults during or after hospitalization for COVID-19. Among 4,866 potentially relevant citations, we included 50 articles. Of these, 19 articles representing 17 studies (2 prospective cohort, 2 retrospective cohort, and 13 cross-sectional) enrolled ≥ 200 participants and provide the best available evidence. The remaining 31 included samples of fewer than 200 people and therefore are less likely to present reproducible results. Findings are summarized in Table 1.
<table>
<thead>
<tr>
<th>Rapid Evidence Review Question</th>
<th>Results &amp; supporting evidence</th>
</tr>
</thead>
</table>
| **KQ1** Among adults who have been hospitalized for COVID-19, what is the prevalence of MH disorders during or after hospitalization? | In 1 fair-quality cross-sectional study, the prevalence of MH symptoms during hospitalization was:  
- **Depression symptoms:** 42.0%  
- **Anxiety symptoms:** 34.9%  
In 5 fair-quality studies, the prevalence of MH symptoms in the 3 months following hospitalization was:  
- **Depression symptoms:** 9-65.7% (1 prospective cohort, 3 cross-sectional)  
- **Anxiety symptoms:** 30-39% (1 prospective cohort)  
- **Insomnia symptoms:** 24-39.6% (1 prospective cohort)  
- **Obsessive compulsive symptoms:** 19.6-26% (1 prospective cohort)  
- **PTSD symptoms:** 9.5-15.4% (1 prospective cohort, 1 cross-sectional) |
| **KQ2** How often do adults without preexisting MH conditions who have been hospitalized for COVID-19 develop new MH symptoms or a new MH diagnosis? | In 1 good-quality retrospective cohort study, the incidence of receiving a new MH disorder diagnosis in the 6 months following hospitalization was:  
- **Anxiety disorder:** 6.9%  
- **Mood disorder:** 4.5%  
- **Substance use disorder:** 2.1%  
- **Insomnia:** 3.1%  
- **Psychotic disorder:** 0.9% |
| **KQ2a** How often do adults without preexisting MH conditions who have been hospitalized for COVID-19 develop new MH symptoms or a new MH diagnosis compared to those with COVID-19 treated only in outpatient settings? | In 1 good-quality retrospective cohort study, hospitalized patients were at higher risk of receiving the following new MH disorder diagnoses compared to non-hospitalized patients:  
- **Anxiety disorder:** HR 1.49 [1.34–1.65]  
- **Mood disorder:** HR 1.53 [1.33–1.75]  
- **Substance use disorder:** HR 1.68 [1.40–2.01]  
- **Insomnia:** HR 1.49 [1.28–1.74]  
- **Psychotic disorder:** HR 2.77 [1.99–3.85] |
<p>| <strong>KQ2b</strong> How often do adults without preexisting MH conditions who have been hospitalized for COVID-19 develop new MH symptoms or a new MH diagnosis compared to adults hospitalized for other causes? | No evidence. |</p>
<table>
<thead>
<tr>
<th>Rapid Evidence Review Question</th>
<th>Results &amp; supporting evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>KQ2c)</strong> Does the probability of developing new MH symptoms or diagnosis during or after hospitalization for COVID-19 vary by patient characteristics (e.g., age, sex, race/ethnicity, comorbidities), COVID-19 disease severity, or level of care?</td>
<td>Evidence from 4 fair-quality cross-sectional studies (1 prospective cohort &amp; 3 cross-sectional) of patients with low or unclear rates of preexisting MH disorders indicate <strong>female sex</strong> and <strong>more severe COVID-19</strong> are the 2 characteristics most consistently associated with worse MH outcomes. There were mixed findings on other pt, disease, and treatment characteristics such as <strong>older age</strong>, <strong>shorter duration of hospitalization</strong> and <strong>receipt of specific treatment such as ventilation and corticosteroids</strong>, with some studies showing an association between these characteristics and worse MH outcomes, and others showing no association or an association with better MH outcomes.</td>
</tr>
</tbody>
</table>
| **KQ3)** How often do adults with preexisting MH conditions who have been hospitalized for COVID-19 experience exacerbation of MH symptoms? | In 1 fair-quality prospective cohort study, the prevalence of MH symptoms in the 3 months following hospitalization for COVID-19 among those with a MH history were:  
- **Depression symptoms:** 26%  
- **PTSD symptoms:** 27%  
- **Anxiety symptoms:** 50%  
- **Obsessive-compulsive symptoms:** 39%  
- **Insomnia symptoms:** 33% |
<p>| <strong>KQ3a)</strong> How often do adults with preexisting MH conditions who have been hospitalized for COVID-19 experience exacerbation of MH symptoms compared to those with COVID-19 treated only in outpatient settings? | No evidence. |
| <strong>KQ3b)</strong> How often do adults with preexisting MH conditions who have been hospitalized for COVID-19 experience exacerbation of MH symptoms compared to adults hospitalized for other causes? | No evidence. |
| <strong>KQ3c)</strong> Does the probability of exacerbating MH symptoms during or after hospitalization for COVID-19 vary by patient characteristics (e.g., age, sex, race/ethnicity, comorbidities), COVID-19 disease severity, or level of care? | No evidence. |
| <strong>KQ4)</strong> How often and what kinds of MH care do adults access during or after hospitalization for COVID-19? | One fair-quality prospective cohort study of 892 hospitalized pts found that 89 (10%) required psychiatric consultation. Of note, 23 out of 89 (25%) pts had a prior neuropsychiatric diagnosis. Another fair-quality retrospective cohort study of 339 hospitalized COVID-19 pts reported that 3 out of 19 (16%) readmitted pts had a psychiatric illness as their reason for readmission; however psychiatric diagnoses were present upon initial admission for 2 out of 3 (67%) of these pts. |</p>
<table>
<thead>
<tr>
<th>Rapid Evidence Review Question</th>
<th>Results &amp; supporting evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>KQ4a)</strong> Does the type or extent of MH care used by adults during or after COVID-19 hospitalization differ compared to before hospitalization?</td>
<td>No evidence.</td>
</tr>
<tr>
<td><strong>KQ4b)</strong> Does the type or extent of MH care utilization differ for adults hospitalized for COVID-19 compared to adults receiving outpatient treatment for COVID-19?</td>
<td>No evidence.</td>
</tr>
<tr>
<td><strong>KQ4c)</strong> Does the type or extent of MH care utilization differ for adults hospitalized for COVID-19 compared to adults hospitalized for other causes?</td>
<td>No evidence.</td>
</tr>
<tr>
<td><strong>KQ4d)</strong> Does the type or extent of MH care utilization during or after hospitalization for COVID-19 vary by patient characteristics (eg, age, sex, race/ethnicity, comorbidities), COVID-19 disease severity, or level of care?</td>
<td>In the fair-quality prospective study of 892 hospitalized patients, the 89 pts who required psychiatric consultation were more likely to require oxygen therapy, consequent ICU transfer, and mechanical ventilation. Pts requiring MH consultation were more likely to have presence of chronic medical disease and/or prior neuropsychiatric diagnosis.</td>
</tr>
<tr>
<td><strong>KQ5)</strong> What are the MH care resource needs among adults who have been hospitalized for COVID-19?</td>
<td>59% of hospitalized pts report at least some need for psychological guidance in rehabilitation (1 poor-quality cross-sectional study)</td>
</tr>
</tbody>
</table>

*Abbreviations: GAD = Generalized Anxiety Disorder; HR= Hazard Ratio; MDD = Major Depressive Disorder; MH = Mental health; Pt = Patient*
The primary limitation of the methods used for this rapid review is that a single reviewer rated studies for inclusion, assessed quality, and abstracted data with second reviewer verification, rather than standard dual independent assessment. This process may have resulted in missing eligible studies or data. This risk was reduced by establishing explicit inclusion criteria for studies, developing and using a piloted data abstraction tool, and creating a key to rate each study according to Joanna Briggs Institute quality criteria.

There were several important limitations of the included primary studies. Only 2 analyses of 1 study were good quality. The other 16 studies were either fair or poor quality, commonly due to limited measurement or reporting of participants’ preexisting MH disorders, comorbidities, and COVID-19 severity.

Future research should examine 3 primary gaps:

- Compare patients who have been hospitalized for COVID-19 to relevant control groups.
- Report and account for potential confounders, particularly preexisting mental health disorders, medications, and medical comorbidities.
- Determine the mental health care utilization and resource/treatment needs of patients after discharge for COVID-19.

As of March 2021, we identified 2 prospective cohort, 2 retrospective cohort, and 13 cross-sectional studies that provide the best available evidence on MH outcomes among people hospitalized for COVID-19. Evidence from primarily fair-quality studies suggests that many patients experience MH symptoms such as depression, anxiety, and insomnia during and in the 3 months following hospitalization for COVID-19. However, patients infrequently receive a new MH disorder diagnosis in the 6 months following hospitalization. Some patients – such as women and those with more severe COVID-19 – may be at higher risk of poor MH outcomes. Future research should compare patients hospitalized for COVID-19 to those hospitalized for other reasons and evaluate mental health treatment utilization and resource needs following hospitalization.
EVIDENCE BRIEF

INTRODUCTION

PURPOSE

The ESP Coordinating Center (ESP CC) is responding to a request from VA Central Office for an evidence brief on mental health outcomes of adults who have been hospitalized for COVID-19. Findings from this evidence brief will be used to inform national VA planning efforts to support Veterans after hospital discharge for COVID-19.

BACKGROUND

In March 2020, the World Health Organization (WHO) declared the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus which causes coronavirus disease 2019 (COVID-19), a pandemic.1 As of June 2021, over 175 million people have been confirmed to have had COVID-19 and over 3 million have died worldwide.2 Although most people with COVID-19 experience no symptoms or mild fever, cough, shortness of breath, or fatigue, approximately 1 in 7 experience severe symptoms that require hospitalization.3 Life-threatening complications of COVID-19 include bacterial pneumonia, sepsis, acute respiratory distress syndrome, and multi-organ failure.3 Those who are over 65 years old with underlying medical conditions (including but not limited to hypertension, obesity, chronic lung disease, diabetes, and cardiovascular disease) are at higher risk of hospitalization and death.4 Among those hospitalized for COVID-19, 32% have been admitted to the intensive care unit (ICU), 19% required mechanical ventilation, and 17% have died in the hospital.5

Addressing complications of COVID-19 may require invasive procedures, including the administration of sedation and/or paralytic agents and intensive intravascular monitoring. These interventions interfere with a patient’s ability to respond to and understand their providers, environment, and treatment. Dexamethasone (a steroid), which is a treatment for people hospitalized with COVID-19, is commonly associated with MH side effects such as anxiety and psychosis.6 In addition, the ICU setting is stressful due to frequent alarms, flashing lights, and providers moving in and out of rooms donning personal protective equipment that can prevent patients from seeing and recognizing faces.7 This environmental stress is likely compounded for patients with COVID-19 by isolation from family, friends, and other support systems that results from restrictive hospital visitation policies employed to reduce the risk of COVID-19 transmission.8 Hospitalization and isolation requirements may also cause a significant disruption in work, resulting in significant financial hardship and distress. Those with COVID-19 may also worry about transmission to and burden on their loved ones or caregivers.

As a result of the stress of being hospitalized for a serious, highly transmissible illness during a pandemic, experts warn that patients who are hospitalized with COVID-19 are at particularly high risk of developing mental health symptoms or experiencing exacerbation or relapse of existing or past mental health disorders.9-11 A systematic review evaluating outcomes after the 2002 SARS and 2012 MERS pandemics indicates many patients with serious infections experienced anxiety (35.7%) and insomnia (41.9%) during the acute phase of their illness and some developed post-traumatic stress disorder (PTSD) (32.2%), depression (14.9%), and anxiety disorders (14.8%) after recovery.12 Additionally, research has shown patients hospitalized for
other illnesses often experience MH symptoms and report problems sleeping while hospitalized. For example, 50% of patients hospitalized for congestive heart failure report experiencing depression symptoms during hospitalization, and patients who are hospitalized for any illness report waking up more and having worse sleep quality in the hospital than at home. Additionally, research on ICU patients has indicated MH disorders that develop after a serious illness can be significant and long-lasting.

The current social environment may also contribute to greater risk of mental health disorders for hospitalized patients with COVID-19. Recent studies on the effects of the COVID-19 pandemic show that general populations have a high prevalence of depression, anxiety, insomnia, and acute stress, and therefore those who have been hospitalized are likely to return to home or work environments that are more stressful or significantly changed from pre-pandemic environments. In addition to stress-related development or exacerbation of mental health disorders, research on previous epidemics with similar pathogens suggests possible biological pathways for increased prevalence of mental health disorders. For example, hospitalized patients with COVID-19 may experience neurologic symptoms such as stroke and encephalopathy during and after their hospitalization, which can impact both acute and chronic mental health.

In June 2020, the Department of Veterans Affairs (VA) Central Office requested that the VA Evidence Synthesis Program (ESP) produce 3 rapid evidence reviews on post-acute care needs for adults who have had COVID-19. The first 2 reviews focus on major organ damage and rehabilitation needs, respectively. This is the third review in the series, focused on mental health needs of adults who have been hospitalized for COVID-19. In general, Veterans who receive care at the VA are older and have more comorbidities than adults in the general population (16% of Veterans at the VA report 5 or more conditions vs 3% of general population), putting them at higher risk for contracting COVID-19. Veterans who receive care at the VA also have a high prevalence of preexisting mental health disorders including depression (13.5%), PTSD (9.3%), substance use disorders (8.3%), anxiety disorders (4.8%), and serious mental illness (3.7%), which could be exacerbated by a COVID-19 hospitalization. The purpose of this review is to evaluate the prevalence of mental health disorders and assess mental health care needs among adults hospitalized for COVID-19 to assist the VA in supporting this population of Veterans. The VA ESP published a report synthesizing studies that had been published as of October 2020; this updated report synthesizes studies published as of March 2021.

**SCOPE**

This rapid review compares the prevalence of mental health disorders and clinical features among adults who have been hospitalized for COVID-19 to relevant comparison groups, assesses whether the prevalence of mental health disorders varies by patient and disease characteristics, and ascertains mental health care utilization and resource needs for adults following hospitalization for COVID-19.

**KEY QUESTIONS AND ELIGIBILITY CRITERIA**

Key Questions and eligibility criteria (population, intervention, comparator, outcome, and timing) appear in Table 2. We included cross-sectional and cohort studies and excluded case series and case reports. We included insomnia as an outcome of interest as it is often symptomatic of another underlying MH disorder.
### Table 2. Key Questions and Eligibility Criteria

<table>
<thead>
<tr>
<th>Key Question</th>
<th>Population</th>
<th>Comparator</th>
<th>Outcomes</th>
<th>Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td>1) Among adults who have been hospitalized for COVID-19, what is the prevalence of MH disorders during or after hospitalization?</td>
<td>Adults who have been hospitalized for COVID-19</td>
<td>None</td>
<td>Prevalence of MH disorders, including both diagnoses and symptoms. Specific MH disorders of interest are mood disorders, anxiety disorders, trauma-related disorders, psychotic disorders, and substance use disorders; excluding cognitive disorders such as delirium and dementia</td>
<td>During or after hospitalization</td>
</tr>
<tr>
<td>2) How often do adults without preexisting MH conditions who have been hospitalized for COVID-19 develop new MH symptoms or a new MH diagnosis?</td>
<td>Adults without preexisting MH conditions who have been hospitalized for COVID-19 vs before hospitalization</td>
<td>New MH symptoms or a new MH diagnosis</td>
<td>During or after hospitalization</td>
<td></td>
</tr>
<tr>
<td>2a) How often do adults without preexisting MH conditions who have been hospitalized for COVID-19 develop new MH symptoms or a new MH diagnosis compared to those with COVID-19 treated only in outpatient settings?</td>
<td>Adults without preexisting MH conditions who have been hospitalized for COVID-19 vs adults without preexisting MH conditions who received outpatient treatment for COVID-19</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2b) How often do adults without preexisting MH conditions who have been hospitalized for COVID-19 develop new MH symptoms or a new MH diagnosis compared to adults hospitalized for other causes?</td>
<td>Adults without preexisting MH conditions who have been hospitalized for COVID-19 vs adults without preexisting MH conditions who have been hospitalized for other causes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2c) Does the probability of developing new MH symptoms or diagnosis during or after hospitalization for COVID-19 vary by patient characteristics (eg, age, sex, race/ethnicity, comorbidities), COVID-19 disease severity, or level of care?</td>
<td>Subgroups vs each other</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3) How often do adults with preexisting MH conditions who have been hospitalized for COVID-19 experience exacerbation of MH symptoms?</td>
<td>Adults with preexisting MH conditions who have been hospitalized for COVID-19 vs before hospitalization</td>
<td>Exacerbation of MH symptoms</td>
<td>During or after hospitalization</td>
<td></td>
</tr>
<tr>
<td>3a) How often do adults with preexisting MH conditions who have been hospitalized for COVID-19</td>
<td>Adults with preexisting MH conditions who have been hospitalized for COVID-19 vs adults with preexisting MH conditions who have been hospitalized for other causes</td>
<td>Exacerbation of MH symptoms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key Question</td>
<td>Population</td>
<td>Comparator</td>
<td>Outcomes</td>
<td>Timing</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
<td>------------</td>
<td>----------</td>
<td>--------</td>
</tr>
<tr>
<td>experience exacerbation of MH symptoms compared to those with COVID-19 treated only in outpatient settings?</td>
<td>hospitalized for COVID-19</td>
<td>received outpatient treatment for COVID-19</td>
<td>vs adults with preexisting MH conditions who have been hospitalized for other causes</td>
<td>Subgroups vs each other</td>
</tr>
<tr>
<td>3b) How often do adults with preexisting MH conditions who have been hospitalized for COVID-19 experience exacerbation of MH symptoms compared to adults hospitalized for other causes?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3c) Does the probability of exacerbating MH symptoms during or after hospitalization for COVID-19 vary by patient characteristics (eg, age, sex, race/ethnicity, comorbidities), COVID-19 disease severity, or level of care?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4) How often and what kinds of MH care do adults access during or after hospitalization for COVID-19?</td>
<td>Adults who have been hospitalized for COVID-19</td>
<td>None</td>
<td>MH care utilization (eg, health care appointments, prescriptions filled, etc)</td>
<td>During or after hospitalization</td>
</tr>
<tr>
<td>4a) Does the type or extent of MH care used by adults during or after COVID-19 hospitalization differ compared to before hospitalization?</td>
<td></td>
<td></td>
<td>vs before hospitalization</td>
<td></td>
</tr>
<tr>
<td>4b) Does the type or extent of MH care utilization differ for adults hospitalized for COVID-19 compared to adults receiving outpatient treatment for COVID-19?</td>
<td></td>
<td></td>
<td>vs adults who received outpatient treatment for COVID-19</td>
<td></td>
</tr>
<tr>
<td>4c) Does the type or extent of MH care utilization differ for adults hospitalized for COVID-19 compared to adults hospitalized for other causes?</td>
<td></td>
<td></td>
<td>vs adults who have been hospitalized for other causes</td>
<td>Subgroups vs each other</td>
</tr>
<tr>
<td>4d) Does the type or extent of MH care utilization during or after hospitalization for COVID-19 vary by patient characteristics (eg, age, sex, race/ethnicity, comorbidities), COVID-19 disease severity, or level of care?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5) What are the MH care resource needs among adults who have been hospitalized for COVID-19?</td>
<td>Adults who have been hospitalized for COVID-19</td>
<td>None</td>
<td>MH care resource needs identified by patients or caregivers</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: MH = mental health
METHODS

SEARCHES AND STUDY SELECTION

To identify articles relevant to the key questions, a research librarian searched Ovid MEDLINE, the WHO COVID-19 database, PsycINFO, and CINAHL, as well as systematic review databases using terms for COVID-19, mental health, and hospitalization from December 2019 to March 2021 (see Supplementary Materials for complete search strategies). Additional citations were identified from hand-searching reference lists and consultation with content experts. We limited the search to published and indexed articles involving human subjects available in the English language. Study selection was based on the eligibility criteria described above. Detailed information in inclusion/exclusion criteria are available in the Supplementary Materials. Titles, abstracts, and full-text articles were reviewed for inclusion by 1 investigator and verified another. All disagreements were resolved by consensus.

Using a best evidence approach, we made a post-hoc decision to only conduct quality assessment, data extraction, and strength of evidence assessments of studies that included ≥200 participants. Our rationale is that larger studies likely provide more reliable prevalence estimates. While the smaller literature base available for our prior reports necessitated relying on studies with smaller samples, the increase in published literature available for this update allowed for a focus on studies with larger sample sizes in this report.

QUALITY ASSESSMENT AND DATA EXTRACTION

We used predefined criteria to rate the internal validity of included studies of ≥200 participants. We used checklists from the Joanna Briggs Institute (JBI) to assess the internal validity of cross-sectional and cohort studies. We extracted study-level data including study characteristics, population, comparator, and outcomes for studies of ≥200 participants. All data abstraction and internal validity ratings were first completed by 1 reviewer then verified by another. All disagreements were resolved by consensus.

STRENGTH OF EVIDENCE ASSESSMENT

We graded the strength of the evidence of studies ≥200 participants based on the AHRQ Methods Guide for Comparative Effectiveness Reviews. Although this method is designed for intervention studies, we applied the concepts to the non-intervention studies, including risk of bias (includes study design and aggregate quality), consistency, directness, and precision of the evidence. Strength of evidence was graded for each key outcome measure and ratings ranged from high to insufficient, reflecting our confidence that the prevalence estimates reflect an unbiased and precise estimate of the true prevalence.

SYNTHESIS OF DATA

Because of the variety of outcomes and outcome measurements used by these studies, we synthesized data narratively.
LIVING REVIEW

This is the last update of a living review. We made the decision to retire the review as several of our conclusions are supported by moderate strength of evidence, and we do not expect new evidence to substantially change our conclusions.

The complete description of our full methods can be found on the PROSPERO international prospective register of systematic reviews (http://www.crd.york.ac.uk/PROSPERO/; registration number CRD42020199557).
RESULTS

The literature flow diagram (Figure 1) summarizes the results of the search and study selection processes. Among 4,866 potentially relevant citations, we included 50 articles. Nineteen of these articles (representing 2 prospective cohort, 2 retrospective cohort and 13 cross-sectional studies) enrolled ≥ 200 participants. These larger studies provide the best available evidence to answer our review questions, as they provide more reliable estimates of prevalence than smaller studies. Results from these 19 articles are described in detail in the “Results” and “Discussion” sections. Citations and limited data extraction of the 31 included articles that enrolled fewer than 200 participants are available in the Supplementary Materials. The Supplementary Materials also include detailed data abstraction and quality assessment for the 19 included and prioritized articles.

Of the 19 prioritized articles, 3 were conducted entirely or primarily in the United States, 6 in China, 2 in Italy, 2 in the UK, 2 in Turkey, 2 in Iran, 1 in Bangladesh, and 1 in Norway. Study size varied from 200 to 236,379 participants, although most included between 200 and 1,000 participants. Nine articles measured outcomes during hospitalization, 9 measured outcomes up to 3 months post-hospitalization, and 1 measured outcomes up to 6 months post-hospitalization.

Patient characteristics varied across articles. Overall, mean age varied from 35 to 60 years, and the percentage who were female ranged from 8% to 65%. Medical comorbidities were inconsistently reported across articles, but those that did report comorbidities reported high prevalence (e.g., 5 studies reported that 29% to 59% of patients had a comorbidity, underlying illness, or chronic medical condition). Race/ethnicity was also inconsistently reported. Of the 2 studies that reported participants’ race/ethnicity, both were conducted in the United States. Two articles reported outcomes from 1 retrospective cohort study of participants with COVID-19 in the United States (N=62,354 in the first article; N=236,379 in the second). These articles reported a large percentage of cohort participants were Black (18.8% to 23.6% of participants in each article were Black, compared to 13.4% of US population that is Black). The other study examined a smaller cohort (N=339) of hospitalized patients with COVID-19 in Rhode Island and reported 37% were Hispanic and 16% were Black – both of which are roughly double the percentage of the general population of Rhode Island that are Hispanic and Black (16.3% and 8.5%, respectively). The high proportion of Black and Hispanic patients hospitalized with COVID-19 included in these studies reflects the health inequities exposed in national trends of patients hospitalized with COVID-19.

In terms of outcomes, most studies reported the prevalence of symptoms of MH disorders (including depression, anxiety, PTSD, obsessive-compulsive, and insomnia). A few studies reported the incidence of MH diagnoses (including mood disorders, anxiety disorders, psychotic disorders, substance use disorders, and insomnia). Additionally, a few studies reported on MH care utilization and resource needs, but data were limited.

Overall, only 2 analyses of the same study were good quality, 11 studies were fair quality, and 5 studies were poor quality. Among fair-quality studies, common methodological limitations included limited measurement or reporting of participants’ preexisting MH disorders, comorbidities, and COVID-19 severity. Poor-quality studies had
additional limitations, including a lack of information on how COVID-19 was ascertained and use of unvalidated instruments to measure outcomes. Because we have extremely low confidence in the results of these poor-quality studies, we do not report results in the following sections except when they provide the only available data on a certain outcome.
LITERATURE FLOW

Figure 1: Literature Flowchart

Records identified through database searching (n=11,411)
- Medline = 3,241
- CDSR = 3
- CINAHL = 2,135
- WHO = 5,303
- PsycINFO = 729

Records identified through reference lists and grey literature searching (n=9)

Records remaining after removal of duplicates (n=4,866)

Excluded (n=4,681)

Records remaining after title and abstract review (n=185)

Excluded (n=135)
- Ineligible population (n=36)
- Ineligible intervention (n=2)
- Ineligible outcome (n=30)
- Ineligible study design (n=11)
- Ineligible publication type (n=38)
- Outdated/ineeligible SR (n=2)
- Language (n=1)
- Preprint (n=9)
- Duplicates (n=5)
- Could not find FT (n=1)

Records remaining after full-text review and included in synthesis (n=50)
KEY QUESTION 1: Among adults who have been hospitalized for COVID-19, what is the prevalence of MH disorders during or after hospitalization?

One fair-quality prospective cohort study with 2 associated publications (N=402 and N=226)\textsuperscript{25,26} and 5 fair-quality cross-sectional studies\textsuperscript{32,36,38,40,43} (N=281 to N=1,002) reported a high prevalence of MH symptoms among patients with COVID-19 during and in the 3 months following hospitalization (Table 3). One fair-quality prospective cohort study\textsuperscript{25} also reported that changes in the severity of MH symptoms varied by disorder between 1-3 months of discharge, with some symptoms becoming less severe and others becoming more severe.

During hospitalization, approximately 4 out of 10 patients with COVID-19 experienced depression symptoms and 3 out of 10 experienced anxiety symptoms.\textsuperscript{40} PTSD, obsessive-compulsive symptoms, psychosis, and insomnia were not assessed in studies of hospitalized patients. The prevalence of anxiety symptoms was similar in the 3-month period post discharge as during the hospitalization period.\textsuperscript{25,26,32} Studies also found approximately 1 out of 10 people hospitalized for COVID-19 experienced PTSD symptoms or met criteria for a PTSD diagnosis,\textsuperscript{25,26,32,43} 3 out of 10 experienced insomnia, and 2 out of 10 experienced obsessive compulsive symptoms within 3 months of leaving the hospital.\textsuperscript{25,26} The prevalence of depression was highly variable across studies conducted within 3 months of hospital discharge (9-66%).\textsuperscript{25,26,32,36,38} No studies in the post-discharge period assessed the prevalence of psychotic disorder.

Findings on the prevalence of mental health disorders were generally of similar magnitude across studies. However, this was not the case with depression, where prevalence estimates ranged from 9% to 66%. It is possible part of this variance is due the wide range of measures used across studies as well as differences in the choice of cut-off point for determining if someone has depression symptoms. The lowest prevalence estimate (9%) comes from a study\textsuperscript{25} (N=226) that reported participants as having depression if they scored 8 or higher on the 13-item Beck Depression Inventory. The same study found the prevalence of depression was 28\% when using a score of 50 or higher on the Zung Self-Rating Depression Scale. The highest prevalence estimate (65.7\%) comes from a study\textsuperscript{32} (N=675) that reported that 19\% of participants had moderate-severe symptoms and 46.7\% had mild symptoms for a total of 65.7\% with any depression symptoms.

While most studies reported prevalence of MH symptoms at 1 time point, 1 single-center, fair-quality prospective cohort study\textsuperscript{25} reported changes across time. This study found that PTSD symptoms of COVID-19 survivors typically decreased post-discharge from the 1-month to the 3-month follow up (IES-R: F = 21.29, p = 0.001; PCL-5: F = 9.07, p = 0.003). These patients also generally experienced a decrease in anxiety symptoms (STAI-state: F = 11.28, p = 0.001) and insomnia symptoms (WHIIRS: F = 9.36, p = 0.003). However, there was no overall change in depression symptoms (measured using ZSDS), and patients’ obsessive compulsive symptoms tended to worsen from the 1-month to 3-month follow-up appointments (F = 4.84, p = 0.030).\textsuperscript{25}

Overall, we have low confidence in these findings, as most are only supported by 1-3 studies (\textit{ie}, had low precision), and findings on the prevalence of depression symptoms varied between studies (\textit{ie}, were inconsistent).
Table 3. Prevalence of MH Disorders in Patients Hospitalized for COVID-19

<table>
<thead>
<tr>
<th>Disorder</th>
<th>During hospitalization</th>
<th>0-3 months post-discharge</th>
<th>3+ months post-discharge</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depression or mood disorder</td>
<td>42.0% depression symptoms&lt;sup&gt;40&lt;/sup&gt;</td>
<td>9-65.7% depression symptoms&lt;sup&gt;25,26,32,36,38&lt;/sup&gt;</td>
<td>No data from prioritized studies</td>
</tr>
<tr>
<td></td>
<td>19% moderate-severe depression symptoms&lt;sup&gt;32&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anxiety</td>
<td>34.9% anxiety symptoms&lt;sup&gt;40&lt;/sup&gt;</td>
<td>30-39.0% anxiety symptoms&lt;sup&gt;25,26&lt;/sup&gt;</td>
<td>No data from prioritized studies</td>
</tr>
<tr>
<td></td>
<td>10.4% moderate-severe anxiety symptoms&lt;sup&gt;32&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTSD</td>
<td>No data from prioritized studies</td>
<td>9.5-15.4% PTSD symptoms&lt;sup&gt;25,26,43&lt;/sup&gt;</td>
<td>No data from prioritized studies</td>
</tr>
<tr>
<td></td>
<td>12.4% PTSD diagnosis&lt;sup&gt;32&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obsessive-compulsive Sleep disorders</td>
<td>No data from prioritized studies</td>
<td>19.6-26% obsessive compulsive symptoms&lt;sup&gt;25,26&lt;/sup&gt;</td>
<td>No data from prioritized studies</td>
</tr>
<tr>
<td></td>
<td>No data from prioritized studies</td>
<td>24-39.6% insomnia symptoms&lt;sup&gt;25,26&lt;/sup&gt;</td>
<td>No data from prioritized studies</td>
</tr>
</tbody>
</table>

Abbreviations: GAD=Generalized Anxiety Disorder; PTSD=Post-traumatic Stress Disorder

Prioritized studies were those that included ≥ 200 participants and were either fair or good quality. The table does not include studies of <200 pts. The following studies also do not appear in the table, as they were poor quality: Chen 2021, Li 2020, Moradian 2020, Moayed 2021, Wang 2020 & Zhang 2020. Ma 2020 also does not appear in the table, as the study only reported data for those with severe COVID-19.

**KEY QUESTION 2: How often do adults without preexisting MH conditions who have been hospitalized for COVID-19 develop new MH symptoms or a new MH diagnosis?**

A good-quality, retrospective cohort study<sup>29</sup> of over 230,000 people from the TriNetX Analytics Network found that approximately 4.5% of hospitalized patients were diagnosed with a mood disorder for the first time within 6 months of their COVID-19 diagnosis. Within the same time period, an estimated 6.9% of hospitalized COVID-19 survivors were diagnosed with an anxiety disorder for the first time, 3.1% were diagnosed with insomnia for the first time, 2.1% were diagnosed with a substance use disorder for the first time, and 0.9% were diagnosed with a psychotic disorder for the first time. Strengths of this study include its large sample size, long follow-up time (6 months), and the fact that it was designed to detect incidence of new MH disorder diagnoses. However, authors provided limited information on the hospitals that comprise the TriNetX database, making it difficult to gauge generalizability to other hospital settings.

A fair-quality, prospective cohort study<sup>25</sup> (N=226) reported the prevalence of MH symptoms 3 months after COVID-19 hospitalization among patients without a MH history. The prevalence of MH symptoms were as follows:

- Depression symptoms: 5% (BDI-13 ≥8) to 23% (ZSDS ≥ 50)
• PTSD symptoms (PCL-5 ≥33): 6%
• Anxiety symptoms (STAI-Y state ≥40): 21%
• Insomnia symptoms (WHIIRS ≥9): 22%
• Obsessive compulsive symptoms (OCI ≥21) 18%.

Overall, we have moderate confidence in estimates of the incidence of receiving a first MH disorder diagnoses within 6 months of being hospitalized for COVID-19, as these estimates are based on a large, good-quality cohort study. We have low confidence in the estimates of MH symptom prevalence among those without a MH history, as the study supporting this finding only included 226 participants (ie, had low precision).

KEY QUESTION 2A: How often do adults without preexisting MH conditions who have been hospitalized for COVID-19 develop new MH symptoms or a new MH diagnosis compared to those with outpatient COVID-19?

One good-quality retrospective cohort study of the TriNetX Analytics Network found that patients who had been hospitalized with COVID-19 were at higher risk of being diagnosed with a mood disorder (HR 1.53 [1.33–1.75]), anxiety disorder (HR 1.49 [1.34–1.65]), psychotic disorder (HR 2.77 [1.99–3.85]), substance use disorder (HR 1.68 [1.40–2.01]) and insomnia (HR 1.49 [1.28–1.74]) for the first time compared to outpatients with COVID-19. This analysis and a previously conducted analysis on a smaller cohort of patients from the same dataset found that hospitalized patients have a 40% increased risk of being diagnosed with a new psychiatric disorder within 3 months and 55% increased risk of being diagnosed with a new mood, anxiety or psychotic disorder within 6 months compared to outpatients. Strengths of both analyses include their large sample sizes, long follow-up time (between 3-6 months), and the fact that they were designed to detect incidence of new MH disorders. However, as noted previously, there was limited information about the hospitals that comprise the TriNetX database.

One fair-quality prospective cohort study and 3 fair-quality cross-sectional studies provide indirect evidence on the development of new MH symptoms by reporting the comparative prevalence of MH symptoms among hospitalized patients versus outpatients with COVID-19. All of the studies looked at populations with unclear prevalence of preexisting MH disorders. One cross-sectional study (N=1,002) found a higher prevalence of depression symptoms among hospitalized patients compared to outpatients with COVID-19 (63% vs 44% on PHQ 9; p<.001). A second cross-sectional study (N=13,049) found hospitalized patients with respiratory symptoms had more PTSD symptoms than outpatients without respiratory symptoms. A third cross-sectional study (N=583) similarly found higher PCL-5 scores among hospitalized patients than outpatients (mean 12.4 vs 9.7; p=.042) but noted PTSD diagnoses (as indicated by DSM-5 criteria) were similar between groups (9.5% vs 7%). By contrast, the prospective cohort study (N=402) found that hospitalization did not have an independent effect on MH symptoms measured a mean of 1 month after discharge. Of note, participants in this study were recruited after presenting to the Emergency Department (300 were subsequently
admitted to the hospital while the other 102 were managed at home), so the outpatient group likely had more severe symptoms than most outpatients with COVID-19.

Overall, we have moderate confidence hospitalized patients are at increased risk of being diagnosed with a new psychiatric disorder, including mood, anxiety, psychotic, substance use disorders, as well as insomnia as this finding is supported by a large, good-quality, retrospective cohort study. We have low confidence hospitalized patients have higher rates of MH symptoms, as the prevalence of preexisting MH disorders (i.e., indirect) was unclear in studies examining symptoms and sample sizes were considerably smaller (i.e., low precision).

**KEY QUESTION 2B: How often do adults without preexisting MH conditions who have been hospitalized for COVID-19 develop new MH symptoms or a new MH diagnosis compared to adults hospitalized for other causes?**

We identified no evidence addressing this question.

**KEY QUESTION 2C: Does the probability of developing new MH symptoms or diagnosis during or after hospitalization for COVID-19 vary by patient characteristics (e.g., age, sex, race/ethnicity, comorbidities), COVID-19 disease severity, or level of care?**

Four studies (1 prospective cohort and 3 cross-sectional) examined the association between patient characteristics, COVID-19 disease severity, level of care and MH symptoms among populations with either low or unclear prevalence of preexisting MH conditions (Table 4).

In terms of patient characteristics, female sex was associated with worse depression and anxiety symptoms during hospitalization and worse depression, anxiety, obsessive-compulsive, and insomnia symptoms post-discharge. Findings were mixed with respect to post-discharge PTSD symptoms. Female sex was associated with worse PTSD symptoms in 1 prospective cohort study, but there was no such association in a cross-sectional study. Older age was associated with worse depression symptoms during hospitalization, but not with PTSD symptoms post-discharge. There was no association between number of comorbidities and PTSD symptoms post-discharge. No studies reported on the association between race/ethnicity and MH disorder diagnoses or symptoms.

In terms of COVID-19 disease characteristics, COVID-19 severity was associated with worse anxiety, PTSD, and depression symptoms post-discharge. In terms of level of care, longer duration of hospitalization was associated with less severe depression, PTSD, obsessive-compulsive, and insomnia symptoms post-discharge in a prospective cohort study. However, duration of hospitalization was not associated with depression or anxiety symptoms during hospitalization in a cross-sectional study. Receipt of ICU care was associated with depression symptoms post-discharge. Receipt of ventilation, however, was not associated with depression, anxiety, or PTSD symptoms post-discharge. Receipt of corticosteroids was associated with higher risk of anxiety symptoms and lower risk of PTSD symptoms post-discharge. Overall, we
have low confidence in these findings, as each association was only examined in 1-3 studies \((ie, \) had low precision), and many findings were inconsistent across studies.
Table 4. Prevalence of MH Disorders Among Patients Hospitalized for COVID-19 by Patient Characteristics, COVID-19 Disease Severity, and Level of Care

<table>
<thead>
<tr>
<th>MH Disorder</th>
<th>Sex</th>
<th>Age</th>
<th>Comorbidities</th>
<th>COVID-19 Disease Severity</th>
<th>Level and type of care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depression</td>
<td>1 DH and 1 PD study found females had worse depression symptoms.</td>
<td>1 DH study found being over 50 years old was associated with depression symptoms.</td>
<td>No data from prioritized studies</td>
<td>1 PD study found COVID-19 severity was associated with depression symptoms</td>
<td>1 PD study found receipt of ventilation not associated with depression symptoms, but receipt of ICU care was associated with depression symptoms.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 PD study found duration of hospitalization associated with better depression symptoms while 1 DH study found no association.</td>
</tr>
<tr>
<td>Anxiety</td>
<td>2 DH &amp; 1 PD study found female sex was associated with anxiety symptoms.</td>
<td>No data from prioritized studies</td>
<td>No data from prioritized studies</td>
<td>1 PD study found COVID-19 severity was associated with anxiety symptoms</td>
<td>1 PD study found receipt of ventilation not correlated with anxiety symptoms, but receipt of corticosteroids was associated with anxiety symptoms.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 PD study found duration of hospitalization was not associated with anxiety symptoms.</td>
</tr>
<tr>
<td>PTSD</td>
<td>1 PD study found females had worse PTSD symptoms.</td>
<td>1 PD study found no association between age and PTSD symptoms.</td>
<td>1 PD study found no association between number of comorbidities and PTSD symptoms.</td>
<td>1 PD study found COVID-19 severity was associated with PTSD symptoms</td>
<td>1 PD study found receipt of ventilation not correlated with PTSD symptoms, but receipt of corticosteroids was associated with lower risk of PTSD symptoms.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 PD study found duration of hospitalization associated with better PTSD symptoms.</td>
</tr>
<tr>
<td>Obsessive-compulsive</td>
<td>1 PD study found females had worse obsessive-compulsive symptoms.</td>
<td>No data from prioritized studies</td>
<td>No data from prioritized studies</td>
<td>No data from prioritized studies</td>
<td>1 PD study found duration of hospitalization associated with better obsessive-compulsive symptoms.</td>
</tr>
<tr>
<td>Sleep disorders</td>
<td>1 PD study found females had worse insomnia symptoms.</td>
<td>No data from prioritized studies</td>
<td>No data from prioritized studies</td>
<td>No data from prioritized studies</td>
<td>1 PD study found duration of hospitalization associated with better insomnia symptoms.</td>
</tr>
</tbody>
</table>

Abbreviations: DH=During hospitalization; PD=Post-discharge; PTSD=Post-traumatic Stress Disorder. Prioritized studies were those that included ≥ 200 participants and were either fair or good quality. The table does not include studies of < 200 pts. Excluded Chen 2021 & Wang 2021 from table as they were poor quality.
KEY QUESTION 3: How often do adults with preexisting MH conditions who have been hospitalized for COVID-19 experience exacerbation of MH symptoms?

A fair-quality prospective cohort study\(^{25}\) (N=226) reported the prevalence of MH symptoms 3 months after COVID-19 hospitalization among patients with a MH history were as follows:

- Depression symptoms: 26% (BDI-13 $\geq 8$) to 40% (ZDS $\geq 50$)
- PTSD symptoms (PCL-5 $\geq 33$): 27%
- Anxiety symptoms (STAI-Y state $\geq 40$): 50%
- Obsessive compulsive symptoms (OCI $\geq 21$): 39%
- Insomnia symptoms (WHIIRS $\geq 9$): 33%

A good-quality retrospective cohort study\(^{29}\) of the TriNetX Analytics Network (N=236,379) and a cross-sectional study provide additional, indirect evidence to address this question. In the retrospective cohort study,\(^{29}\) the incidence of receiving any mental health disorder diagnosis in the 6 months following a COVID-19 diagnosis were as follows for hospitalized patients: 14.7% for mood disorder, 16.4% for anxiety disorder, 2.9% for psychotic disorder, 8.6% for substance use disorder, and 6% for insomnia disorder. Because the incidence of receiving any mental health disorder diagnosis was consistently higher than the incidence of receiving a first mental health disorder diagnosis (14.7% vs 4.5% for mood disorder, 16.4 vs 6.9% for anxiety disorder, 2.9% vs 0.9% for psychotic disorder; 8.6% vs 2.1% for substance use disorder, and 6% vs 3.1% for insomnia disorder), we can deduce that at least some of the patients who received a mental health diagnosis during the 6-month time period were experiencing an exacerbation of a pre-existing, diagnosed MH condition.

In the cross-sectional study\(^{26}\) (N=402), authors found that psychiatric history had a significant effect on current self-reported MH symptoms (p<.0001). Specifically, patients with a previous psychiatric history (i.e., diagnosis of MDD, GAD, panic attack disorder, bipolar disorder, social phobia, eating disorder, or other MH disorder) had worse symptoms of anxiety, depression, PTSD, insomnia, and obsessive-compulsive disorder an average of 32 days after discharge than those without a previous psychiatric history. Of note, in this study only 300 participants were hospitalized with COVID-19, with the other 102 participants managed at home. The study does not stratify results by hospitalization status.

Overall, we have low confidence in these findings, as only a single, relatively small study\(^{25}\) directly reported the prevalence of MH symptoms among those with a MH history.

KEY QUESTION 3A: How often do adults with preexisting MH conditions who have been hospitalized for COVID-19 experience exacerbation of MH symptoms compared to those with outpatient COVID-19?

We identified no evidence addressing this question.
KEY QUESTION 3B: How often do adults with preexisting MH conditions who have been hospitalized for COVID-19 experience exacerbation of MH symptoms compared to adults hospitalized for other causes?

We identified no evidence addressing this question.

KEY QUESTION 3C: Does the probability of exacerbating MH symptoms during or after hospitalization for COVID-19 vary by patient characteristics (eg, age, sex, race/ethnicity, comorbidities), COVID-19 disease severity, or level of care?

We identified no evidence addressing this question.

KEY QUESTION 4: How often and what kinds of MH care do adults access during or after hospitalization for COVID-19?

One fair-quality cross-sectional study27 reported that 89 out of 892 hospitalized COVID-19 patients (10%) required psychiatric consultation during hospitalization. The most common reasons for psychiatric consultation in these 89 patients were psychomotor agitation/restlessness (25.8%), impairment of sleep (23.6%), evaluation of prior psychiatric treatment (16.7%), anxiety/fear (14.6%), and suicidal ideation (9%). Delirium was the most common diagnosis made (38.2%), followed by adjustment disorder (27.0%), depressive disorder (19.1%), and anxiety disorder (11.2%). Of note, 23 out of the 89 patients (25%) who had a psychiatric consultation had a prior neuropsychiatric diagnosis. This study is limited by excluding patients in ICU settings.

Another fair-quality cross-sectional study28 of 339 hospitalized COVID-19 patients examined the reasons for readmission of 19 patients who were readmitted. Authors reported that 3 out of 19 (16%) readmitted patients had a psychiatric illness as their reason for readmission; 2 of those patients had psychiatric illness of initial presentation. Therefore, COVID-19 is unlikely to be the etiology for these psychiatric symptoms.

Evidence is insufficient to draw conclusions on MH care utilization during or after hospitalization for COVID-19, due to the limited available data.

KEY QUESTION 4A: Does the type or extent of MH care used by adults during or after COVID-19 hospitalization differ compared to before hospitalization?

We identified no evidence addressing this question.

KEY QUESTION 4B: Does the type or extent of MH care utilization differ for adults hospitalized for COVID-19 compared to adults receiving outpatient treatment for COVID-19?

We identified no evidence addressing this question.
**KEY QUESTION 4C:** Does the type or extent of MH care utilization differ for adults hospitalized for COVID-19 compared to adults hospitalized for other causes?

We identified no evidence addressing this question.

**KEY QUESTION 4D:** Does the type or extent of MH care utilization during or after hospitalization for COVID-19 vary by patient characteristics (e.g., age, sex, race/ethnicity, comorbidities), COVID-19 disease severity, or level of care?

One fair-quality study of 891 hospitalized COVID-19 patients examined outcomes among those who received psychiatric consultations. Patients requiring MH consultation were more likely to require oxygen therapy, consequent ICU transfer, and mechanical ventilation. Patients requiring MH consultation were more likely to have presence of chronic medical disease and/or prior neuropsychiatric diagnosis. We identified no evidence regarding age, sex, or race/ethnicity and mental health utilization. Evidence is insufficient to draw conclusions on type or extent of MH care utilization by patient characteristics during or after hospitalization for COVID-19, due to the limited available data.

**KEY QUESTION 5:** What are the MH care resource needs among adults who have been hospitalized for COVID-19?

There is limited available evidence on MH resource needs among people hospitalized for COVID-19. A poor-quality study found 59% of hospitalized patients reported at least some need for psychological guidance in rehabilitation; however, the study does not provide any additional information on what is meant by “guidance.” Evidence is therefore insufficient to draw conclusions on MH care resource needs based on the paucity of available data.
SUMMARY AND DISCUSSION

We conducted a rapid evidence review to determine the prevalence of MH disorders among adults hospitalized for COVID-19, to compare this to the prevalence of MH disorders in relevant comparison groups, and to determine MH care utilization and resource needs post-hospitalization for patients with COVID-19. Although a few systematic reviews have examined the prevalence of MH disorders during the COVID-19 pandemic, they have either focused on the general population,79 or evaluated patients with COVID-19 together with SARS and MERS patients.12 To our knowledge, this is the first evidence review on the prevalence of mental health disorders specifically among patients who have been hospitalized for COVID-19. This is the last update of the review, adding literature published in the 8 months after the initial review. In this update, we prioritized evidence from 19 articles25-43 that reported data from 17 studies of ≥ 200 participants.

The best available evidence from these 17 studies indicates there may be a high prevalence of MH symptoms during and in the 3 months after hospitalization for COVID-19 (approximately 40% of patients may experience depression symptoms, 30% anxiety symptoms, 20% insomnia symptoms, 20% obsessive-compulsive symptoms, and 10% PTSD symptoms). However, the incidence of receiving a new MH disorder diagnosis in the 6 months after hospitalization is probably much lower than the reported symptom rate (range of 2-7% of patients were diagnosed with substance use, insomnia, anxiety, or mood disorder for the first time). These data suggest that while some patients may experience mental health symptoms after hospitalization for COVID-19, most do not go on to develop a new mental health disorder. As with any serious medical condition, clinicians should provide patients who were recently hospitalized for COVID-19 with general MH resources (eg, stress management strategies; local MH contact information in case of new, persistent, or worsening MH symptoms). Additionally, hospitalization for COVID-19 may represent a point of contact for patients who do not frequently utilize healthcare services; this provides clinicians with a unique opportunity to screen these patients for mental health disorders.

Hospitalized COVID-19 patients are probably at a slightly elevated risk of receiving a first MH disorder diagnosis 6 months after COVID-19 diagnosis compared to outpatients with COVID-19. Because we did not find studies comparing hospitalized COVID-19 patients to patients hospitalized for other reasons, we do not know if this increased risk is due to hospitalization for COVID-19 specifically or hospitalization generally. Furthermore, although there have been case reports80,81 of psychotic episodes following COVID-19 diagnosis, the incidence of receiving a new psychotic disorder diagnosis in the 6 months following hospitalization for COVID-19 is likely extremely low (around 1%).29 It is noteworthy, however, that the risk is higher in hospitalized patients than outpatients (HR 2.77 [1.99–3.85]). Overall, clinicians should be aware that hospitalized patients may be at slightly elevated risk of developing new MH disorders than outpatients with COVID-19, and that some patients may develop a psychotic disorder after hospitalization for COVID-19. However, psychosis is extremely rare.

Finally, we found that female sex and COVID-19 severity are the 2 patient and disease characteristics most consistently associated with worse MH outcomes. Given women are more likely to report and seek help for MH symptoms than men,82 this could be the result of sex-related reporting biases, rather than a true difference in symptoms. COVID-19 severity was associated with worse anxiety, PTSD, and depression symptoms post-discharge. Studies had mixed findings on other patient, disease, and treatment characteristics such as older age, duration
of hospitalization and receipt of specific treatment such as ventilation and corticosteroids, with some studies showing an association with MH outcomes and others showing no association.

**LIMITATIONS**

There were limitations to both our rapid review methods and limitations of our included studies.

**Rapid Review Limitations**

The primary limitation of our rapid review methods is that we had a single reviewer assess articles for inclusion, abstract data, and assess study quality, with second reviewer verification. This could have resulted in missing eligible studies or data, although we attempted to reduce this risk by establishing explicit inclusion criteria for studies, developing and using a piloted data abstraction tool, and developing a key for determining whether a study met each of JBI’s quality criteria.

A second limitation of our rapid review methods is that we focused our synthesis on the 19 prioritized articles of ≥ 200 participants that provided the best available evidence, rather than all 50 articles. As a result, we do not include an exhaustive account of all outcomes reported by all studies. For example, 2 studies (N=33 and N=109) reported low rates of suicidal ideation in hospitalized patients with COVID-19 (3/33 or 9% in 1 study and 3/109 or 3% in the other), which is an outcome not measured in larger studies. However, given the small sample sizes of these 2 studies and low base rates of suicidal ideation among hospitalized patients, larger studies are needed for reliable estimates of suicidal ideation prevalence. This is an area in need of future research.

**Primary Study Limitations**

There were several important limitations of our 19 prioritized articles. As described in the “Results” section, only 2 analyses of 1 study were high quality. The other 16 studies were fair or poor quality, with common methodological limitations including not reporting or accounting for the prevalence of preexisting MH disorders in analyses, limited information on other medical comorbidities that could be confounders, and limited information on the severity of COVID-19 and how COVID-19 was ascertained among participants.

**GAPS AND FUTURE RESEARCH**

For the most part, new studies addressed the gaps in evidence described in the March 2021 report. However, a few important knowledge gaps remain.

- Researchers should compare patients who have been hospitalized for COVID-19 to relevant control groups. More comparative studies are needed as these can help to determine the extent to which outcomes are driven by the COVID-19 illness itself or by other factors such as the experience of hospitalization, severity of COVID-19 symptoms, level of care needed such as ICU versus non-ICU, and other factors.

- Researchers should report and account for potential confounders, particularly preexisting mental health disorders, medications, and medical comorbidities. As discussed in the “Limitations” section, few studies reported whether participants had preexisting mental health disorders. This is problematic because the prevalence of post-hospitalization mental
health disorders is likely influenced by the prevalence of pre-hospitalization mental health disorders. For cross-sectional studies, researchers should at minimum report the proportion of participants with specific preexisting mental health disorders. For comparative cross-sectional studies or longitudinal studies, researchers should report the proportion of participants with specific preexisting mental health disorders for each comparison group. Ideally, researchers would account for preexisting mental health disorders in prevalence estimates (eg, by separately reporting the proportion of participants with mental health disorders among those who had preexisting disorders and the proportion of participants with new-onset mental health disorders, and by estimating adjusted prevalence or risk ratios). Similarly, researchers should also report patients’ preexisting medications and medical comorbidities. Finally, wherever possible, researchers should also report on patients’ social determinants of health (such as homelessness and social support), as these factors are likely to be associated with the pre-hospitalization prevalence of mental health disorders.

- Researchers should assess the mental health care utilization and resource needs of patients after their discharge for COVID-19. While we identified 3 studies that provide some information about the MH care needs of COVID-19 patients during or after hospitalization, the studies were relatively small, 1 was low quality, and most importantly, they provided limited information about patient MH care preferences or needs. While new MH diagnoses are rare after hospitalization for COVID-19, it remains unclear whether traditional methods of diagnosing and treating mental health disorders are sufficient for these patients, or if additional or novel assessments, treatment strategies, or resources should be provided. Given the absence of evidence on patients’ post-hospitalization needs and preferences, continuing to rely on existing, standard procedures to assess patients’ mental and physical health needs after hospitalization is likely appropriate. For those with new anxiety or depression symptoms, the WHO recommends providing support strategies including mental health first aid, stress management, and brief psychological interventions based on cognitive behavioral therapy (CBT) as first-line therapy and benzodiazepines as second-line therapy for those with severe distress. If anxiety and depression symptoms persist, patients should consult with mental health professionals for further evaluation and treatment. While the American Psychological Association and American Psychiatric Association do not provide clinical practice guidelines on caring for patients with COVID-19 specifically, they provide guidance on caring for patients with mental health disorders generally, as well as high-level guidance for identifying signs of COVID-19-related mental health issues and providing mental health care remotely.

Going forward, developing mental health screening tools tailored to the specific needs of patients who have been hospitalized for COVID-19 may be warranted. Screening items could include assessment of mental health symptoms related to hospitalization as well as other concerns stemming from the COVID-19 pandemic that could impact mental health (eg, loss of employment, separation from loved ones, anxiety about possible reinfection, etc).
EVIDENCING NATURE OF COVID-19 AND MENTAL HEALTH

In the year since we first searched for evidence on this topic, the nature of the COVID-19 pandemic has changed. In late 2020 and early 2021, the FDA authorized 3 vaccines for emergency use in the United States. The subsequent increase in the number of people vaccinated against COVID-19 has corresponded with a decline in the number of new, daily COVID-19 cases in the United States (from 290,000 on Jan 6, 2021 to 8,000 on Jun 20, 2021). The rate of new COVID-19 hospitalizations per 100,000 people per day in the United States has also declined tremendously (from 4.85 on Jan 6, 2021 to 0.56 on Jun 20, 2021). Additionally, there are now a variety of FDA-authorized treatments available for patients hospitalized for COVID-19, including tocilizumab and remdesivir.

Although there has been much progress to contain the SARS-CoV-2 virus this past year, numerous variants have emerged, some of which may be associated with more serious illness. Currently, the spread of the Delta variant has corresponded to increases in COVID-19 cases and hospitalizations in the United States. As a result, it will be important for researchers to continue to evaluate mental health outcomes among those hospitalized for COVID-19, especially in places with high rates of hospitalizations.

Due to the different ways the pandemic is evolving, factors such as vaccination, treatment, variants, and policy changes could influence MH outcomes for patients hospitalized for COVID-19. For example, many healthcare systems are allowing patients hospitalized for COVID-19 to have visitors if the visitors are vaccinated. Being able to see family and friends has the potential to reduce depression, anxiety, and PTSD symptoms among hospitalized COVID-19 patients. Additionally, the knowledge that treatments are available may also help reduce stress and anxiety among patients hospitalized for COVID-19. Regardless of the way COVID-19 evolves, assessing the impact of COVID-19 hospitalization on MH outcomes will continue to be important.
CONCLUSIONS

We identified a total of 2 prospective cohort, 2 retrospective cohort, and 13 cross-sectional studies that provide the best available evidence on MH outcomes during and after hospitalization for COVID-19 through March 2021. Evidence from primarily fair-quality studies suggests that many patients experience MH symptoms such as depression, anxiety, and insomnia during and in the 3 months following hospitalization for COVID-19. However, patients infrequently receive a new MH disorder diagnosis in the 6 months following hospitalization. Some patients (such as women and those with more severe COVID-19) may be at higher risk of poor MH outcomes. Future research should compare patients hospitalized for COVID-19 to those hospitalized for other reasons and evaluate mental health treatment utilization and resource needs following hospitalization.
ACKNOWLEDGMENTS

This topic was developed in response to a nomination by Joe Francis MD, Chief Improvement and Analytics Officer for the Office of the Under Secretary for Health for the purpose of informing national VA planning efforts to support Veterans after hospital discharge for COVID-19. The scope was further developed with input from the Operational Partners, the ESP Coordinating Center, and the review team.

In designing the study questions and methodology at the outset of this report, the ESP consulted several technical and content experts. Broad expertise and perspectives were sought. Divergent and conflicting opinions are common and perceived as healthy scientific discourse that results in a thoughtful, relevant systematic review. Therefore, in the end, study questions, design, methodologic approaches, and/or conclusions do not necessarily represent the views of individual technical and content experts.

The authors gratefully acknowledge Payten Sonnen for help with data extraction and administrative support, Nicholas Parr, PhD, for feedback on previous drafts, and the following individuals for their contributions to this project:

**Operational Partners**

Operational partners are system-level stakeholders who have requested the report to inform decision-making. They recommend Technical Expert Panel (TEP) participants; assure VA relevance; help develop and approve final project scope and timeframe for completion; provide feedback on draft report; and provide consultation on strategies for dissemination of the report to field and relevant groups.

**Joe Francis, MD**  
Chief Improvement and Analytics Officer  
*Office of the Under Secretary for Health*

**Clifford Smith, MD**  
Deputy Director  
*Office of Mental Health Operations*

**David Carroll, PhD**  
Executive Director  
*Office of Mental Health & Suicide Prevention*

**Peer Reviewers**

The Coordinating Center sought input from external peer reviewers to review the draft report and provide feedback on the objectives, scope, methods used, perception of bias, and omitted evidence. Peer reviewers must disclose any relevant financial or non-financial conflicts of interest. Because of their unique clinical or content expertise, individuals with potential conflicts may be retained. The Coordinating Center and the ESP Center work to balance, manage, or mitigate any potential nonfinancial conflicts of interest identified.
REFERENCES


